These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29524760)

  • 1. New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases.
    Di Pauli F; Reindl M; Berger T
    Mult Scler Relat Disord; 2018 May; 22():35-37. PubMed ID: 29524760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?
    Di Pauli F; Berger T
    Front Immunol; 2018; 9():2753. PubMed ID: 30555462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort.
    Ketelslegers IA; Van Pelt DE; Bryde S; Neuteboom RF; Catsman-Berrevoets CE; Hamann D; Hintzen RQ
    Mult Scler; 2015 Oct; 21(12):1513-20. PubMed ID: 25662345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
    Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
    Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
    Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
    Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
    J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Armangue T; Capobianco M; de Chalus A; Laetitia G; Deiva K;
    Eur J Paediatr Neurol; 2020 Nov; 29():22-31. PubMed ID: 33191096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and MRI phenotype of children with MOG antibodies.
    Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
    Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The spectrum of MOG autoantibody-associated demyelinating diseases.
    Reindl M; Di Pauli F; Rostásy K; Berger T
    Nat Rev Neurol; 2013 Aug; 9(8):455-61. PubMed ID: 23797245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms.
    Musso G; Nosadini M; Gallo N; Sartori S; Seguso M; Plebani M
    Neurol Sci; 2020 Sep; 41(9):2553-2559. PubMed ID: 32242290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
    Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
    J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
    Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
    Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.
    O'Connor KC; Appel H; Bregoli L; Call ME; Catz I; Chan JA; Moore NH; Warren KG; Wong SJ; Hafler DA; Wucherpfennig KW
    J Immunol; 2005 Aug; 175(3):1974-82. PubMed ID: 16034142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?
    Breza M; Koutsis G; Tzartos JS; Velonakis G; Evangelopoulos ME; Tzanetakos D; Karagiorgou K; Angelopoulou G; Kasselimis D; Potagas C; Anagnostouli M; Stefanis L; Kilidireas C
    Mult Scler Relat Disord; 2019 Aug; 33():67-69. PubMed ID: 31158804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?
    Reindl M; Jarius S; Rostasy K; Berger T
    Curr Opin Neurol; 2017 Jun; 30(3):295-301. PubMed ID: 28248700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options.
    Lee YJ; Nam SO; Ko A; Kong J; Byun SY
    Clin Exp Pediatr; 2021 Mar; 64(3):103-110. PubMed ID: 32403899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Myelin oligodendrogliocyte glycoprotein: the structure, functions, role in pathogenesis of demyelinating disorders].
    Chekhonin VP; Semenova AV; Gurina OI; Dmitrieva TB
    Biomed Khim; 2003; 49(5):411-23. PubMed ID: 16119093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
    Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies.
    Hino-Fukuyo N; Haginoya K; Nakashima I; Sato DK; Takahashi T; Misu T; Fujihara K; Hirose M; Kakisaka Y; Uematsu M; Kobayashi T; Kure S
    Brain Dev; 2015 Oct; 37(9):849-52. PubMed ID: 25748628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.